25 results on '"Schiano Moriello, Nicola"'
Search Results
2. SARS-CoV-2 in Kidney Transplant Patients: A Real-Life Experience
- Author
-
Biagio Pinchera, Lorenzo Spirito, Lucia Ferreri, Roberto La Rocca, Giuseppe Celentano, Antonio Riccardo Buonomo, Maria Foggia, Riccardo Scotto, Stefano Federico, Ivan Gentile, Rosa Carrano, “Federico II” COVID-19 Team, Amicone Maria, Borrelli Francesco, Buonomo Antonio Riccardo, Cattaneo Letizia, Conte Maria Carmela Domenica, Cotugno Mariarosaria, Di Filippo Giovanni, Foggia Maria, Gallicchio Antonella, Gentile Ivan, Giaccone Agnese, Lanzardo Amedeo, Mercinelli Simona, Minervini Fulvio, Piccione Amerigo, Pinchera Biagio, Reynaud Laura, Salemi Fabrizio, Sardanelli Alessia, Schiano Moriello Nicola, Scordino Fabrizio, Scotto Riccardo, Stagnaro Francesca, Tosone Grazia, Viceconte Giulio, Zappulo Emanuela, and Zotta Irene
- Subjects
kidney transplant ,SARS-CoV-2 ,COVID-19 ,transplant ,immunosuppression ,Medicine (General) ,R5-920 - Abstract
BackgroundThe COVID-19 pandemic has significantly impacted the management of solid organ transplant recipients and on clinical evolution in post-transplantation. Little is known on the impact of SARS-CoV-2 infection in these patients. The severity and lethality of this disease in solid organ transplant patients are higher thanin the general population. This study aims to describe clinical characteristics of SARS-CoV-2 infection in solid organ transplant recipients followed in our center.MethodsIn this observational study, we enrolled all kidney transplant recipientsattending the A.O.U. Federico II of Naples from March 2020 to January 2021. For each patient we evaluated the epidemiological and clinical characteristics as well as outcome.ResultsWe enrolled 369 kidney transplant patients (229, male, 62%). Of these, 51 (13.8%) acquired SARS-CoV-2 infection and 29 showed symptomatic disease. Of the 51 patients with the infection, 48 (94.11%) had at least one comorbidity and such comorbidities did not constitute a risk factor for a more severe disease. Hospitalization was necessary for 7 (13.7%) patients. Of these, 2 required low-flow oxygen supplementation, 3 non-invasive/high flow ventilation and 2 invasive ventilation. Finally, 2 patients died.ConclusionsOur study shows a lower mortality and hospitalization rate compared to figures available in the literature (4% vs. 13–30% and 14% vs. 32–100%, respectively). Furthermore, the comorbidities examined (hypertension, dyslipidemia, and diabetes) did not constitute a risk factor for a more severe disease condition in this patient category. Further studies with larger sample size are necessary to confirm these data.
- Published
- 2022
- Full Text
- View/download PDF
3. Serological Response and Clinical Protection of Anti-SARS-CoV-2 Vaccination and the Role of Immunosuppressive Drugs in a Cohort of Kidney Transplant Patients
- Author
-
Pinchera Biagio, Carrano Rosa, Schiano Moriello Nicola, Salemi Fabrizio, Piccione Amerigo, Zumbo Giulia, Scotto Riccardo, Villari Riccardo, Romano Paolo, Spirito Lorenzo, Gentile Ivan, and Federico II COVID Team
- Subjects
SARS-CoV-2 ,COVID-19 ,vaccination ,transplant ,immunosuppression ,serological response ,Microbiology ,QR1-502 - Abstract
Vaccination against SARS-CoV2 represents a key weapon to prevent COVID-19, but lower response rates to vaccination have frequently been reported in solid organ transplant recipients. The aim of our study was to evaluate the rate of seroconversion to SARS-CoV-2 mRNA vaccines in a cohort of kidney transplant recipients and the potential role of the different immunosuppressive regimens. We conducted an observational retrospective cohort study in kidney transplant patients vaccinated for COVID-19. For each patient, we evaluated IgG anti-S-RBD SARS-CoV-2 titers immediately before the administration of first COVID-19 vaccination dose, 20 days after the first dose and 40 days after the second dose. Moreover, we evaluated the type of immunosuppressive treatment and the incidence of vaccine breakthrough SARS-CoV-2 infection. We enrolled 121 kidney transplant patients vaccinated for COVID-19. At the time of administration of the first vaccine dose, all patients had a negative antibody titer; only 4.1% had positive antibody titers 20 days after the first dose. More than half patients 62 (51%) had protective antibody titers 40 days after the second dose. A total of 18 Solid Organ Transplant Recipients (SOTRs) (14.9%) got a SARS-CoV-2 breakthrough infection during the study period. With regard to immunosuppressive regimen, patients on mycophenolate-based regimen (48.7%) showed the lowest antibody response rates (27.5%) compared to other regimens. Our study confirms that kidney transplant patients show a poor response to two doses of COVID-19 vaccination. Moreover, in our study the use of mycophenolate is significantly associated with a non-response to COVID-19 m-RNA vaccines.
- Published
- 2022
- Full Text
- View/download PDF
4. COVID-19 prophylaxis in immunosuppressed patients: Beyond vaccination
- Author
-
Gentile, Ivan and Schiano Moriello, Nicola
- Subjects
Immunocompromised host -- Care and treatment ,Monoclonal antibodies -- Health aspects ,Company business planning ,Biological sciences - Abstract
Author(s): Ivan Gentile *, Nicola Schiano Moriello Introduction Since early 2020, the Coronavirus Disease 2019 (COVID-19) pandemic has caused hundreds of millions of cases and several million deaths worldwide [1]. [...]
- Published
- 2022
- Full Text
- View/download PDF
5. The Role of CRP POC Testing in the Fight against Antibiotic Overuse in European Primary Care: Recommendations from a European Expert Panel
- Author
-
Gentile, Ivan; https://orcid.org/0000-0002-5199-8451, Schiano Moriello, Nicola; https://orcid.org/0000-0001-8474-4776, Hopstaken, Rogier, Llor, Carl, Melbye, Hasse; https://orcid.org/0000-0002-9773-3141, Senn, Oliver; https://orcid.org/0000-0003-4422-7250, Gentile, Ivan; https://orcid.org/0000-0002-5199-8451, Schiano Moriello, Nicola; https://orcid.org/0000-0001-8474-4776, Hopstaken, Rogier, Llor, Carl, Melbye, Hasse; https://orcid.org/0000-0002-9773-3141, and Senn, Oliver; https://orcid.org/0000-0003-4422-7250
- Abstract
Tackling antibiotic resistance represents one of the major challenges in modern medicine, and limiting antibiotics’ overuse represents the first step in this fight. Most antibiotics are prescribed in primary care settings, and lower respiratory tract infections (LRTIs) are one of the most common indications for their prescription. An expert panel conducted an extensive report on C-reactive protein point-of-care (CRP POC) testing in the evaluation of LRTIs and its usefulness to limit antibiotic prescriptions. The expert panel stated that CRP POC testing is a potentially useful tool to limit antibiotic prescriptions for LRTI in a community setting. CRP POC must be used in conjunction with other strategies such as improved communication skills and the use of other molecular POC testing. Potential barriers to the adoption of CRP POC testing are financial and logistical issues. Moreover, the efficacy in limiting antibiotic prescriptions could be hampered by the fact that, in some countries, patients may gain access to antibiotics even without a prescription. Through the realization of a better reimbursement structure, the inclusion in standardized procedures in local guidelines, and better patient education, CRP point-of-care testing can represent a cornerstone in the fight against antimicrobial resistance.
- Published
- 2023
6. Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study
- Author
-
Gentile, Ivan, Scotto, Riccardo, Schiano Moriello, Nicola, Pinchera, Biagio, Villari, Riccardo, Trucillo, Emilia, Ametrano, Luigi, Fusco, Ludovica, Castaldo, Giuseppe, Buonomo, Antonio Riccardo, Federico Ii Covid Team, null, Gentile, Ivan, Scotto, Riccardo, Schiano Moriello, Nicola, Pinchera, Biagio, Villari, Riccardo, Trucillo, Emilia, Ametrano, Luigi, Fusco, Ludovica, Castaldo, Giuseppe, Buonomo, Antonio Riccardo, and Federico Ii Covid Team, Null
- Subjects
Pharmacology ,Infectious Diseases ,SARS-CoV-2 ,adverse drug reaction ,Drug Discovery ,Immunology ,COVID-19 ,molnupiravir ,Pharmacology (medical) ,nirmatrelvir/ritonavir ,hospitalization ,adverse drug reactions - Abstract
Molnupiravir and nirmatrelvir were the first available oral antivirals (OAs) active against SARS-CoV-2. Trials evaluating the efficacy of OAs involved patients unvaccinated and infected with variants different from those currently circulating. We conducted a retrospective study on patients with confirmed SARS-CoV-2 infection treated with OAs during the omicron surge in Italy in order to provide real-life data on the efficacy and safety of OAs during the omicron surge of the COVID-19 pandemic. Among 257 patients, 56.8% received molnupiravir, while 43.2% received nirmatrelvir/ritonavir. Patients in the molnupiravir group were older, had a lower body mass index, and had a higher rate of chronic heart disease than those treated with nirmatrelvir/ritonavir. Three hospitalizations were recorded in the molnupiravir (2.1%) group and one in the nirmatrelvir/ritonavir (0.9%) group. One patient treated with molnupiravir died. The median time to negativity was 8 days in the nirmatrelvir/ritonavir group vs. 10 days in the molnupiravir group, p < 0.01. We recorded 37 ADRs (mainly dysgeusia, diarrhea, and nausea) in 31 individuals (12.1%). Only two patients (0.8%) treated with molnupiravir terminated treatment due to ADRs. In conclusion, in a population of mostly vaccinated patients treated with OAs, we observed a low rate of hospitalization, death, and adverse drug reactions. These rates were lower than those reported in pivotal trials.
- Published
- 2022
- Full Text
- View/download PDF
7. The Role of CRP POC Testing in the Fight against Antibiotic Overuse in European Primary Care: Recommendations from a European Expert Panel
- Author
-
Gentile, Ivan, primary, Schiano Moriello, Nicola, additional, Hopstaken, Rogier, additional, Llor, Carl, additional, Melbye, Hasse, additional, and Senn, Oliver, additional
- Published
- 2023
- Full Text
- View/download PDF
8. Update on the Management of Surgical Site Infections
- Author
-
Pinchera, Biagio, primary, Buonomo, Antonio Riccardo, additional, Schiano Moriello, Nicola, additional, Scotto, Riccardo, additional, Villari, Riccardo, additional, and Gentile, Ivan, additional
- Published
- 2022
- Full Text
- View/download PDF
9. Impact of oral antiviral therapy against HCV on gut microbiota. A prospective study
- Author
-
Biagio Pinchera, Scotto Riccardo, Zappulo Emanuela, Buonomo Antonio Riccardo, Maraolo Alberto Enrico, Schiano Moriello Nicola, Viceconte Giulio, Cattaneo Letizia, Villari Riccardo, Gison Flavia, De Filippis Francesca, Ercolini Danilo, and Gentile Ivan
- Abstract
The intestinal microbiota plays a fundamental role in physiological homeostasis as well as in pathologic conditions. Hepatitis C virus is the leading cause of chronic liver diseases wordwide. The treatment of this infection has been revolutioned by the availability of direct-acting antiviral agent which guarantee high rate (about 95%) of viral clearance. Few studies have assessed the change in gut microbiota in patients treated with direct-acting antiviral agents against HCV and many aspects still need to be clarified. The aim of the study was to evaluate the effects of antiviral therapy on gut microbiota. We enrolled patients with HCV-related chronic liver disease attending the Infectious Diseases Unit of the A.O.U. Federico II of Naples, from January 2017 to March 2018, treated with DAAs. For each patient, a fecal sample was collected and analyzed for the assessment of the microbial diversity before the start of therapy and by SVR12 time. We exluded patients who received antibiotics in the last 6 months. Twelve patients were enrolled (6 male, 8 genotype 1 (1 subtype 1a), 4 genotype 2). Fibrosis score were F0 in 1 patient, F2 in 1 patient, F3 in 4 patients and cirrhosis in the remaining 6 (all in Child-Pugh class A). All were treated with DAAs for 12 weeks (5 with Paritaprevir-Ombitasvir-Ritonavir-Dasabuvir, 3 with Sofosbuvir-Ledipasvir, 1 with Sofosbuvir-Ribavirin, 1 with Sofosbuvir-Daclatasvir, 1 with Sofosbuvir-Velpatasvir) and 100% achieved SVR12. In all patients, we observed a trend in reduction of potentially pathogenic microorganisms (i.e. Enterobacteriaceae). Furthermore, a trend of increase in α-diversity was observed in patients by SVR12 compared to baseline. This trend was markedly more evident in patients without liver cirrhosis than in those with cirrhosis. Our study shows that viral eradication obtained with DAA is associated with a trend in restoring the heterogeneity of α-diversity and in reducing the percentage of potentially pathogenic microbial species, although this benefit is less evident in patients with cirrhosis. Further studies with larger sample size are necessary to confirm these data.
- Published
- 2022
10. Monoclonal Antibodies against SARS-CoV-2 Infection: Results from a Real-Life Study before the Omicron Surge
- Author
-
Scotto, Riccardo, Buonomo, Antonio Riccardo, Zumbo, Giulia, Di Fusco, Antonio, Esposito, Nunzia, Di Filippo, Isabella, Nobile, Mariano, Pinchera, Biagio, Schiano Moriello, Nicola, Villari, Riccardo, Gentile, Ivan, Federico Ii Covid Team, null, Scotto, Riccardo, Buonomo, Antonio Riccardo, Zumbo, Giulia, Di Fusco, Antonio, Esposito, Nunzia, Di Filippo, Isabella, Nobile, Mariano, Pinchera, Biagio, Schiano Moriello, Nicola, Villari, Riccardo, Gentile, Ivan, and Federico Ii Covid Team, Null
- Subjects
Pharmacology ,Infectious Diseases ,SARS-CoV-2 ,Drug Discovery ,Immunology ,early treatment ,COVID-19 ,serology ,Pharmacology (medical) ,real-life ,immunodeficiency ,monoclonal antibodie ,chronic kidney disease - Abstract
Despite the lightning-fast advances in the management of SARS-CoV after 2 years of pandemic, COVID-19 continues to pose a challenge for fragile patients, who could benefit from early administration of monoclonal antibodies (mAbs) to reduce the risk of severe disease progression. We conducted a prospective study to evaluate the effectiveness of mAbs against SARS-CoV-2 among patients at risk for severe disease progression, namely elderly and those with comorbidities, before the omicron variant surge. Patients were treated with either casirivimab/imdevimab, sotrovimab, or bamlanivimab/etesevimab. The rates and risk factors for clinical worsening, hospitalization, ICU admission and death (unfavorable outcomes) were evaluated. A stratified analysis according to the presence of SARS-CoV-2 IgG was also performed. Among 185 included patients, we showed low rates of unfavorable outcomes (9.2%), which were more frequent in patients with chronic kidney disease (aOR: 10.44, 95% CI: 1.73–63.03; p < 0.05) and basal D-dimer serum concentrations > 600 ng/mL (aOR 21.74, 95% CI: 1.18–397.70; p < 0.05). Patients with negative SARS-CoV-2 serology at baseline showed higher C-reactive protein values compared with patients with positive serology (p < 0.05) and a trend toward a higher admission rate to SICU and ICU compared with patients with positive serology. Our results thus showed, in a real-life setting, the efficacy of mAbs against SARS-CoV-2 before an Omicron surge when the available mabs become not effective.
- Published
- 2022
11. COVID-19 Post-Exposure Evaluation (COPE) Study: Assessing the Role of Socio-Economic Factors in Household SARS-CoV-2 Transmission within Campania Region (Southern Italy)
- Author
-
Gentile, Ivan, Iorio, Martina, Zappulo, Emanuela, Scotto, Riccardo, Maraolo, Alberto Enrico, Buonomo, Antonio Riccardo, Pinchera, Biagio, Muto, Giuseppina, Iervolino, Carmela, Villari, Riccardo, Schiano Moriello, Nicola, Scirocco, Maria Michela, Triassi, Maria, Paternoster, Mariano, Russo, Vincenzo, Viceconte, Giulio, Federico Ii Covid-Team, null, Gentile, Ivan, Iorio, Martina, Zappulo, Emanuela, Scotto, Riccardo, Maraolo, Alberto Enrico, Buonomo, Antonio Riccardo, Pinchera, Biagio, Muto, Giuseppina, Iervolino, Carmela, Villari, Riccardo, Schiano Moriello, Nicola, Scirocco, Maria Michela, Triassi, Maria, Paternoster, Mariano, Russo, Vincenzo, Viceconte, Giulio, and Federico Ii Covid-Team, Null
- Subjects
COVID-19 ,SARS-CoV-2 ,household ,poverty ,regional studies ,Campania (Italy) ,Economic Factor ,Health, Toxicology and Mutagenesis ,Public Health, Environmental and Occupational Health ,Italy ,Retrospective Studie ,Humans ,regional studie ,Economic Factors ,Human ,Retrospective Studies - Abstract
Campania is the sixth poorest region of Italy, and it is the region with the highest income inequality. The secondary attack rates of SARS-CoV-2 among households are found to be substantially heterogeneous among published studies and are influenced by socio-economic factors. We conducted a retrospective study to describe the role of socio-economic factors in the household transmission of SARS-CoV-2 among patients living in Campania Region and referring to “Federico II” Hospital. We interviewed 413 subjects followed-up for COVID-19 between the 8 March 2020 and the 24 May 2021 with the aim to collect demographic, clinical, economic, and social data regarding their household and the index cases. The variables associated with SARS-CoV-2 attack rate higher than 50% among households were higher age (p = 0.023) and higher Charlson Comorbidity Index of the index case (p = 0.023) and, for household characteristics, higher number of families per house (p = 0.02), location of the houses in Naples’ suburbs (Chi2 = 5.3, p = 0.02) and in Caserta City area (Chi2 = 4, p = 0.04), and renting the house compared to owning it (Chi2 = 5.83, p = 0.01). This study confirms the finding described by other authors that household transmission of SARS-CoV-2 is correlated with the income inequality of the analyzed geographical area as well as with the indicators of health and economic wealth of the families, and this correlation also applies to the Campania Region.
- Published
- 2022
12. Inducible Nitric Oxide Synthase (iNOS): Why a Different Production in COVID-19 Patients of the Two Waves?
- Author
-
Gelzo, Monica, primary, Scialò, Filippo, additional, Cacciapuoti, Sara, additional, Pinchera, Biagio, additional, De Rosa, Annunziata, additional, Cernera, Gustavo, additional, Comegna, Marika, additional, Tripodi, Lorella, additional, Schiano Moriello, Nicola, additional, Mormile, Mauro, additional, Fabbrocini, Gabriella, additional, Parrella, Roberto, additional, Corso, Gaetano, additional, Gentile, Ivan, additional, and Castaldo, Giuseppe, additional
- Published
- 2022
- Full Text
- View/download PDF
13. Diabetes and SARS-CoV-2 Infection: The Potential Role of Antidiabetic Therapy in the Evolution of COVID-19.
- Author
-
Pinchera, Biagio, Schiano Moriello, Nicola, Buonomo, Antonio Riccardo, Di Filippo, Isabella, Tanzillo, Anastasia, Buzzo, Giorgio, Villari, Riccardo, and Gentile, Ivan
- Subjects
COVID-19 ,COVID-19 treatment ,SARS-CoV-2 ,HYPOGLYCEMIC agents ,INFECTION - Abstract
Diabetes mellitus represents one of the most frequent comorbidities among patients with COVID-19, constituting a risk factor for a more severe prognosis than that of non-diabetic patients. However, the pathophysiological mechanism underlying this unfavorable outcome is still not completely clear. The goal of our study was to evaluate the potential role of antidiabetic therapy in the evolution of COVID-19. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
14. Monoclonal Antibodies against SARS-CoV-2: Potential Game-Changer Still Underused
- Author
-
Gentile, Ivan, primary, Maraolo, Alberto Enrico, additional, Buonomo, Antonio Riccardo, additional, Nobile, Mariano, additional, Piscitelli, Prisco, additional, Miani, Alessandro, additional, and Schiano Moriello, Nicola, additional
- Published
- 2021
- Full Text
- View/download PDF
15. Disentangling the Association of Hydroxychloroquine Treatment with Mortality in Covid-19 Hospitalized Patients through Hierarchical Clustering
- Author
-
Di Castelnuovo, Augusto, primary, Gialluisi, Alessandro, additional, Antinori, Andrea, additional, Berselli, Nausicaa, additional, Blandi, Lorenzo, additional, Bonaccio, Marialaura, additional, Bruno, Raffaele, additional, Cauda, Roberto, additional, Costanzo, Simona, additional, Guaraldi, Giovanni, additional, Menicanti, Lorenzo, additional, Mennuni, Marco, additional, My, Ilaria, additional, Parruti, Giustino, additional, Patti, Giuseppe, additional, Perlini, Stefano, additional, Santilli, Francesca, additional, Signorelli, Carlo, additional, Stefanini, Giulio, additional, Vergori, Alessandra, additional, Ageno, Walter, additional, Agodi, Antonella, additional, Agostoni, Piergiuseppe, additional, Aiello, Luca, additional, Al Moghazi, Samir, additional, Arboretti, Rosa, additional, Aucella, Filippo, additional, Barbieri, Greta, additional, Barchitta, Martina, additional, Bonfanti, Paolo, additional, Cacciatore, Francesco, additional, Caiano, Lucia, additional, Cannata, Francesco, additional, Carrozzi, Laura, additional, Cascio, Antonio, additional, Castiglione, Giacomo, additional, Ciccullo, Arturo, additional, Cingolani, Antonella, additional, Cipollone, Francesco, additional, Colomba, Claudia, additional, Colombo, Crizia, additional, Crisetti, Annalisa, additional, Crosta, Francesca, additional, Danzi, Gian Battista, additional, D'Ardes, Damiano, additional, de Gaetano Donati, Katleen, additional, Di Gennaro, Francesco, additional, Di Tano, Giuseppe, additional, D'Offizi, Gianpiero, additional, Fusco, Francesco Maria, additional, Gaudiosi, Carlo, additional, Gentile, Ivan, additional, Gianfagna1, Francesco, additional, Giuliano, Gabriele, additional, Graziani, Emauele, additional, Guarnieri, Gabriella, additional, Langella, Valerio, additional, Larizza, Giovanni, additional, Leone, Armando, additional, Maccagni, Gloria, additional, Magni, Federica, additional, Maitan, Stefano, additional, Mancarella, Sandro, additional, Manuele, Rosa, additional, Mapelli, Massimo, additional, Maragna, Riccardo, additional, Marcucci, Rossella, additional, Maresca, Giulio, additional, Marongiu, Silvia, additional, Marotta, Claudia, additional, Marra, Lorenzo, additional, Mastroianni, Franco, additional, Mengozzi, Alessandro, additional, Meschiari, Marianna, additional, Milic, Jovana, additional, Minutolo, Filippo, additional, Mussinelli, Roberta, additional, Mussini, Cristina, additional, Musso, Maria, additional, Odone, Anna, additional, Olivieri, Marco, additional, Palimodde, Antonella, additional, Pasi, Emanuela, additional, Pesavento, Raffaele, additional, Petri, Francesco, additional, Pivato, Carlo A, additional, Poletti, Venerino, additional, Ravaglia, Claudia, additional, Righetti, Giulia, additional, Rognoni, Andrea, additional, Rossato, Marco, additional, Rossi, Ilaria, additional, Rossi, Marianna, additional, Sabena, Anna, additional, Salinaro, Francesco, additional, Sangiovanni, Vincenzo, additional, Sanrocco, Carlo, additional, Schiano Moriello, Nicola, additional, Scorzolini, Laura, additional, Sgariglia, Raffaella, additional, Simeone, Paola Giustina, additional, Spinicci, Michele, additional, Tamburrini, Enrica, additional, Torti, Carlo, additional, Trecarichi, Enrico Maria, additional, Vettor, Roberto, additional, Vianello, Andrea, additional, Vinceti, Marco, additional, Virdis, Agostino, additional, De Caterina, Raffaele, additional, and Iacoviello, Licia, additional
- Published
- 2021
- Full Text
- View/download PDF
16. Disentangling the Association of Hydroxychloroquine Treatment with Mortality in Covid-19 Hospitalized Patients through Hierarchical Clustering
- Author
-
Di Castelnuovo, A, Gialluisi, A, Antinori, A, Berselli, N, Blandi, L, Bonaccio, M, Bruno, R, Cauda, R, Costanzo, S, Guaraldi, G, Menicanti, L, Mennuni, M, My, I, Parruti, G, Patti, G, Perlini, S, Santilli, F, Signorelli, C, Stefanini, G, Vergori, A, Ageno, W, Agodi, A, Agostoni, P, Aiello, L, Al Moghazi, S, Arboretti, R, Aucella, F, Barbieri, G, Barchitta, M, Bonfanti, P, Cacciatore, F, Caiano, L, Cannata, F, Carrozzi, L, Cascio, A, Castiglione, G, Cicullo, A, Cingolani, A, Cipollone, F, Colomba, C, Colombo, C, Crisetti, A, Crosta, F, Danzi, G, D'Ardes, D, de Gaetano Donati, K, Di Gennaro, F, Di Tano, G, D'Offizi, G, Fusco, F, Gaudiosi, C, Gentile, I, Gianfagna1, F, Giuliano, G, Graziani, E, Guarnieri, G, Langella, V, Larizza, G, Leone, A, Maccagni, G, Magni, F, Maitan, S, Mancarella, S, Manuele, R, Mapelli, M, Maragna, R, Marcucci, R, Maresca, G, Marongiu, S, Marotta, C, Marra, L, Mastroianni, F, Mengozzi, A, Meschiari, M, Milic, J, Minutolo, F, Mussinelli, R, Mussini, C, Musso, M, Odone, A, Olivieri, M, Palimodde, A, Pasi, E, Pesavento, R, Petri, F, Pivato, C, Poletti, V, Ravaglia, C, Righetti, G, Rognoni, A, Rossato, M, Rossi, I, Rossi, M, Sabena, A, Salinaro, F, Sangiovanni, V, Sanrocco, C, Schiano Moriello, N, Scorzolini, L, Sgariglia, R, Simeone, P, Spinicci, M, Tamburrini, E, Torti, C, Trecarichi, E, Vettor, R, Vianello, A, Vinceti, M, Virdis, A, De Caterina, R, Iacoviello, L, Di Castelnuovo, Augusto, Gialluisi, Alessandro, Antinori, Andrea, Berselli, Nausicaa, Blandi, Lorenzo, Bonaccio, Marialaura, Bruno, Raffaele, Cauda, Roberto, Costanzo, Simona, Guaraldi, Giovanni, Menicanti, Lorenzo, Mennuni, Marco, My, Ilaria, Parruti, Giustino, Patti, Giuseppe, Perlini, Stefano, Santilli, Francesca, Signorelli, Carlo, Stefanini, Giulio, Vergori, Alessandra, Ageno, Walter, Agodi, Antonella, Agostoni, Piergiuseppe, Aiello, Luca, Al Moghazi, Samir, Arboretti, Rosa, Aucella, Filippo, Barbieri, Greta, Barchitta, Martina, Bonfanti, Paolo, Cacciatore, Francesco, Caiano, Lucia, Cannata, Francesco, Carrozzi, Laura, Cascio, Antonio, Castiglione, Giacomo, Cicullo, Arturo, Cingolani, Antonella, Cipollone, Francesco, Colomba, Claudia, Colombo, Crizia, Crisetti, Annalisa, Crosta, Francesca, Danzi, Gian Battista, D'Ardes, Damiano, de Gaetano Donati, Katleen, Di Gennaro, Francesco, Di Tano, Giuseppe, D'Offizi, Gianpiero, Fusco, Francesco Maria, Gaudiosi, Carlo, Gentile, Ivan, Gianfagna1, Francesco, Giuliano, Gabriele, Graziani, Emauele, Guarnieri, Gabriella, Langella, Valerio, Larizza, Giovanni, Leone, Armando, Maccagni, Gloria, Magni, Federica, Maitan, Stefano, Mancarella, Sandro, Manuele, Rosa, Mapelli, Massimo, Maragna, Riccardo, Marcucci, Rossella, Maresca, Giulio, Marongiu, Silvia, Marotta, Claudia, Marra, Lorenzo, Mastroianni, Franco, Mengozzi, Alessandro, Meschiari, Marianna, Milic, Jovana, Minutolo, Filippo, Mussinelli, Roberta, Mussini, Cristina, Musso, Maria, Odone, Anna, Olivieri, Marco, Palimodde, Antonella, Pasi, Emanuela, Pesavento, Raffaele, Petri, Francesco, Pivato, Carlo A, Poletti, Venerino, Ravaglia, Claudia, Righetti, Giulia, Rognoni, Andrea, Rossato, Marco, Rossi, Ilaria, Rossi, Marianna, Sabena, Anna, Salinaro, Francesco, Sangiovanni, Vincenzo, Sanrocco, Carlo, Schiano Moriello, Nicola, Scorzolini, Laura, Sgariglia, Raffaella, Simeone, Paola Giustina, Spinicci, Michele, Tamburrini, Enrica, Torti, Carlo, Trecarichi, Enrico Maria, Vettor, Roberto, Vianello, Andrea, Vinceti, Marco, Virdis, Agostino, De Caterina, Raffaele, Iacoviello, Licia, Di Castelnuovo, A, Gialluisi, A, Antinori, A, Berselli, N, Blandi, L, Bonaccio, M, Bruno, R, Cauda, R, Costanzo, S, Guaraldi, G, Menicanti, L, Mennuni, M, My, I, Parruti, G, Patti, G, Perlini, S, Santilli, F, Signorelli, C, Stefanini, G, Vergori, A, Ageno, W, Agodi, A, Agostoni, P, Aiello, L, Al Moghazi, S, Arboretti, R, Aucella, F, Barbieri, G, Barchitta, M, Bonfanti, P, Cacciatore, F, Caiano, L, Cannata, F, Carrozzi, L, Cascio, A, Castiglione, G, Cicullo, A, Cingolani, A, Cipollone, F, Colomba, C, Colombo, C, Crisetti, A, Crosta, F, Danzi, G, D'Ardes, D, de Gaetano Donati, K, Di Gennaro, F, Di Tano, G, D'Offizi, G, Fusco, F, Gaudiosi, C, Gentile, I, Gianfagna1, F, Giuliano, G, Graziani, E, Guarnieri, G, Langella, V, Larizza, G, Leone, A, Maccagni, G, Magni, F, Maitan, S, Mancarella, S, Manuele, R, Mapelli, M, Maragna, R, Marcucci, R, Maresca, G, Marongiu, S, Marotta, C, Marra, L, Mastroianni, F, Mengozzi, A, Meschiari, M, Milic, J, Minutolo, F, Mussinelli, R, Mussini, C, Musso, M, Odone, A, Olivieri, M, Palimodde, A, Pasi, E, Pesavento, R, Petri, F, Pivato, C, Poletti, V, Ravaglia, C, Righetti, G, Rognoni, A, Rossato, M, Rossi, I, Rossi, M, Sabena, A, Salinaro, F, Sangiovanni, V, Sanrocco, C, Schiano Moriello, N, Scorzolini, L, Sgariglia, R, Simeone, P, Spinicci, M, Tamburrini, E, Torti, C, Trecarichi, E, Vettor, R, Vianello, A, Vinceti, M, Virdis, A, De Caterina, R, Iacoviello, L, Di Castelnuovo, Augusto, Gialluisi, Alessandro, Antinori, Andrea, Berselli, Nausicaa, Blandi, Lorenzo, Bonaccio, Marialaura, Bruno, Raffaele, Cauda, Roberto, Costanzo, Simona, Guaraldi, Giovanni, Menicanti, Lorenzo, Mennuni, Marco, My, Ilaria, Parruti, Giustino, Patti, Giuseppe, Perlini, Stefano, Santilli, Francesca, Signorelli, Carlo, Stefanini, Giulio, Vergori, Alessandra, Ageno, Walter, Agodi, Antonella, Agostoni, Piergiuseppe, Aiello, Luca, Al Moghazi, Samir, Arboretti, Rosa, Aucella, Filippo, Barbieri, Greta, Barchitta, Martina, Bonfanti, Paolo, Cacciatore, Francesco, Caiano, Lucia, Cannata, Francesco, Carrozzi, Laura, Cascio, Antonio, Castiglione, Giacomo, Cicullo, Arturo, Cingolani, Antonella, Cipollone, Francesco, Colomba, Claudia, Colombo, Crizia, Crisetti, Annalisa, Crosta, Francesca, Danzi, Gian Battista, D'Ardes, Damiano, de Gaetano Donati, Katleen, Di Gennaro, Francesco, Di Tano, Giuseppe, D'Offizi, Gianpiero, Fusco, Francesco Maria, Gaudiosi, Carlo, Gentile, Ivan, Gianfagna1, Francesco, Giuliano, Gabriele, Graziani, Emauele, Guarnieri, Gabriella, Langella, Valerio, Larizza, Giovanni, Leone, Armando, Maccagni, Gloria, Magni, Federica, Maitan, Stefano, Mancarella, Sandro, Manuele, Rosa, Mapelli, Massimo, Maragna, Riccardo, Marcucci, Rossella, Maresca, Giulio, Marongiu, Silvia, Marotta, Claudia, Marra, Lorenzo, Mastroianni, Franco, Mengozzi, Alessandro, Meschiari, Marianna, Milic, Jovana, Minutolo, Filippo, Mussinelli, Roberta, Mussini, Cristina, Musso, Maria, Odone, Anna, Olivieri, Marco, Palimodde, Antonella, Pasi, Emanuela, Pesavento, Raffaele, Petri, Francesco, Pivato, Carlo A, Poletti, Venerino, Ravaglia, Claudia, Righetti, Giulia, Rognoni, Andrea, Rossato, Marco, Rossi, Ilaria, Rossi, Marianna, Sabena, Anna, Salinaro, Francesco, Sangiovanni, Vincenzo, Sanrocco, Carlo, Schiano Moriello, Nicola, Scorzolini, Laura, Sgariglia, Raffaella, Simeone, Paola Giustina, Spinicci, Michele, Tamburrini, Enrica, Torti, Carlo, Trecarichi, Enrico Maria, Vettor, Roberto, Vianello, Andrea, Vinceti, Marco, Virdis, Agostino, De Caterina, Raffaele, and Iacoviello, Licia
- Abstract
The efficacy of hydroxychloroquine (HCQ) in treating SARS-CoV-2 infection is harshly debated, with observational and experimental studies reporting contrasting results. To clarify the role of HCQ in Covid-19 patients, we carried out a retrospective observational study of 4,396 unselected patients hospitalized for Covid-19 in Italy (February–May 2020). Patients’ characteristics were collected at entry, including age, sex, obesity, smoking status, blood parameters, history of diabetes, cancer, cardiovascular and chronic pulmonary diseases, and medications in use. These were used to identify subtypes of patients with similar characteristics through hierarchical clustering based on Gower distance. Using multivariable Cox regressions, these clusters were then tested for association with mortality and modification of effect by treatment with HCQ. We identified two clusters, one of 3,913 younger patients with lower circulating inflammation levels and better renal function, and one of 483 generally older and more comorbid subjects, more prevalently men and smokers. The latter group was at increased death risk adjusted by HCQ (HR[CI95%] = 3.80[3.08-4.67]), while HCQ showed an independent inverse association (0.51[0.43-0.61]), as well as a significant influence of cluster∗HCQ interaction (). This was driven by a differential association of HCQ with mortality between the high (0.89[0.65-1.22]) and the low risk cluster (0.46[0.39-0.54]). These effects survived adjustments for additional medications in use and were concordant with associations with disease severity and outcome. These findings suggest a particularly beneficial effect of HCQ within low risk Covid-19 patients and may contribute to clarifying the current controversy on HCQ efficacy in Covid-19 treatment.
- Published
- 2021
17. Serum KL-6 Could Represent a Reliable Indicator of Unfavourable Outcome in Patients with COVID-19 Pneumonia
- Author
-
Scotto, Riccardo, primary, Pinchera, Biagio, additional, Perna, Francesco, additional, Atripaldi, Lidia, additional, Giaccone, Agnese, additional, Sequino, Davide, additional, Zappulo, Emanuela, additional, Sardanelli, Alessia, additional, Schiano Moriello, Nicola, additional, Stanziola, Anna, additional, Bocchino, Marialuisa, additional, Gentile, Ivan, additional, and Sanduzzi, Alessandro, additional
- Published
- 2021
- Full Text
- View/download PDF
18. Pneumocystis jirovecii Pneumonia in Non-HIV Patients Recovering from COVID-19: A Single-Center Experience.
- Author
-
Gentile, Ivan, Viceconte, Giulio, Lanzardo, Amedeo, Zotta, Irene, Zappulo, Emanuela, Pinchera, Biagio, Scotto, Riccardo, Schiano Moriello, Nicola, Foggia, Maria, Giaccone, Agnese, Messina, Gaetana, Salvatore, Paola, and Buonomo, Antonio Riccardo
- Published
- 2021
- Full Text
- View/download PDF
19. Update on the Management of Surgical Site Infections
- Author
-
Biagio Pinchera, Antonio Riccardo Buonomo, Nicola Schiano Moriello, Riccardo Scotto, Riccardo Villari, Ivan Gentile, Pinchera, Biagio, Buonomo, Antonio Riccardo, Schiano Moriello, Nicola, Scotto, Riccardo, Villari, Riccardo, and Gentile, Ivan
- Subjects
Microbiology (medical) ,Infectious Diseases ,prevention ,risk factor ,treatment ,antibiotic ,prophylaxi ,surgical site infections (SSIs) ,Pharmacology (medical) ,antimicrobial resistance ,General Pharmacology, Toxicology and Pharmaceutics ,Biochemistry ,Microbiology - Abstract
Surgical site infections are an increasingly important issue in nosocomial infections. The progressive increase in antibiotic resistance, the ever-increasing number of interventions and the ever-increasing complexity of patients due to their comorbidities amplify this problem. In this perspective, it is necessary to consider all the risk factors and all the current preventive and prophylactic measures which are available. At the same time, given multiresistant microorganisms, it is essential to consider all the possible current therapeutic interventions. Therefore, our review aims to evaluate all the current aspects regarding the management of surgical site infections.
- Published
- 2022
20. Inducible Nitric Oxide Synthase (iNOS): Why a Different Production in COVID-19 Patients of the Two Waves?
- Author
-
Monica Gelzo, Filippo Scialò, Sara Cacciapuoti, Biagio Pinchera, Annunziata De Rosa, Gustavo Cernera, Marika Comegna, Lorella Tripodi, Nicola Schiano Moriello, Mauro Mormile, Gabriella Fabbrocini, Roberto Parrella, Gaetano Corso, Ivan Gentile, Giuseppe Castaldo, Gelzo, M., Scialo, F., Cacciapuoti, S., Pinchera, B., De Rosa, A., Cernera, G., Comegna, M., Tripodi, L., Moriello, N. S., Mormile, M., Fabbrocini, G., Parrella, R., Corso, G., Gentile, I., Castaldo, G., Gelzo, Monica, Scialò, Filippo, Cacciapuoti, Sara, Pinchera, Biagio, De Rosa, Annunziata, Cernera, Gustavo, Comegna, Marika, Tripodi, Lorella, Schiano Moriello, Nicola, Mormile, Mauro, Fabbrocini, Gabriella, Parrella, Roberto, Corso, Gaetano, Gentile, Ivan, and Castaldo, Giuseppe
- Subjects
Infectious Diseases ,COVID-19 ,nitric oxide ,steroid therapy ,SARS-CoV-2 ,Virology ,Steroid therapy ,Humans ,Nitric Oxide Synthase Type II ,Nitric oxide ,Human - Abstract
Profound clinical differences between the first and second waves of COVID-19 were observed in Europe. Nitric oxide (NO) may positively impact patients with Severe Acute Respiratory Syndrome CoronaVirus-2 (SARS-CoV-2) infection. It is mainly generated by inducible nitric oxide synthase (iNOS). We studied serum iNOS levels together with serum interleukin (IL)-6 and IL-10 in patients with SARS-CoV-2 infection in the first wave (n = 35) and second wave (n = 153). In the first wave, serum iNOS, IL-6, IL-10 levels increased significantly, in line with the World Health Organization (WHO) score severity, while in the second wave, iNOS did not change with the severity. The patients of the second wave showed lower levels of iNOS, IL-6, and IL-10, as compared to the corresponding subgroup of the first wave, suggesting a less severe outcome of COVID-19 in these patients. However, in the severe patients of the second wave, iNOS levels were significantly lower in patients treated with steroids or azithromycin before the hospitalization, as compared to the untreated patients. This suggests an impairment of the defense mechanism against the virus and NO-based therapies as a potential therapy in patients with low iNOS levels.
- Published
- 2022
21. Serological Response and Clinical Protection of Anti-SARS-CoV-2 Vaccination and the Role of Immunosuppressive Drugs in a Cohort of Kidney Transplant Patients
- Author
-
Biagio, Pinchera, Rosa, Carrano, Nicola, Schiano Moriello, Fabrizio, Salemi, Amerigo, Piccione, Giulia, Zumbo, Riccardo, Scotto, Riccardo, Villari, Paolo, Romano, Lorenzo, Spirito, Ivan, Gentile, Federico Ii Covid Team, null, Pinchera, Biagio, Carrano, Rosa, SCHIANO MORIELLO, Nicola, Salemi, Fabrizio, Piccione, Amerigo, Zumbo, Giulia, Scotto, Riccardo, Villari, Riccardo, Romano, Paolo, Spirito, Lorenzo, Gentile, Ivan, and Null, Federico Ii Covid Team
- Subjects
immunosuppression ,COVID-19 Vaccines ,SARS-CoV-2 ,Vaccination ,COVID-19 ,Antibodies, Viral ,Kidney Transplantation ,Transplant Recipients ,Cohort Studies ,Infectious Diseases ,Pharmaceutical Preparations ,Immunoglobulin G ,Virology ,vaccination ,transplant ,serological response ,Humans ,RNA, Viral ,Immunosuppressive Agents ,Retrospective Studies - Abstract
Vaccination against SARS-CoV2 represents a key weapon to prevent COVID-19, but lower response rates to vaccination have frequently been reported in solid organ transplant recipients. The aim of our study was to evaluate the rate of seroconversion to SARS-CoV-2 mRNA vaccines in a cohort of kidney transplant recipients and the potential role of the different immunosuppressive regimens. We conducted an observational retrospective cohort study in kidney transplant patients vaccinated for COVID-19. For each patient, we evaluated IgG anti-S-RBD SARS-CoV-2 titers immediately before the administration of first COVID-19 vaccination dose, 20 days after the first dose and 40 days after the second dose. Moreover, we evaluated the type of immunosuppressive treatment and the incidence of vaccine breakthrough SARS-CoV-2 infection. We enrolled 121 kidney transplant patients vaccinated for COVID-19. At the time of administration of the first vaccine dose, all patients had a negative antibody titer; only 4.1% had positive antibody titers 20 days after the first dose. More than half patients 62 (51%) had protective antibody titers 40 days after the second dose. A total of 18 Solid Organ Transplant Recipients (SOTRs) (14.9%) got a SARS-CoV-2 breakthrough infection during the study period. With regard to immunosuppressive regimen, patients on mycophenolate-based regimen (48.7%) showed the lowest antibody response rates (27.5%) compared to other regimens. Our study confirms that kidney transplant patients show a poor response to two doses of COVID-19 vaccination. Moreover, in our study the use of mycophenolate is significantly associated with a non-response to COVID-19 m-RNA vaccines.
- Published
- 2022
22. Impact of oral antiviral therapy against HCV on gut microbiota. A prospective study.
- Author
-
Pinchera B, Scotto R, Zappulo E, Buonomo AR, Maraolo AE, Schiano Moriello N, Viceconte G, Cattaneo L, Villari R, Gison F, De Filippis F, Ercolini D, and Gentile I
- Subjects
- Male, Humans, Sofosbuvir, Antiviral Agents therapeutic use, Prospective Studies, Hepacivirus genetics, Drug Therapy, Combination, Liver Cirrhosis drug therapy, Liver Cirrhosis complications, Gastrointestinal Microbiome, Hepatitis C, Chronic complications, Macrocyclic Compounds, Hepatitis C drug therapy, Hepatitis C complications
- Abstract
The intestinal microbiota plays a fundamental role in physiological homeostasis as well as in pathologic conditions. Hepatitis C virus is the leading cause of chronic liver diseases worldwide. The treatment of this infection has been revolutionized by the availability of direct-acting antiviral agents which guarantee a high rate (about 95%) of viral clearance. Few studies have assessed the change in the gut microbiota of patients treated with direct-acting antiviral agents against HCV, and many aspects still need to be clarified. The aim of the study was to evaluate the effects of antiviral therapy on gut microbiota. We enrolled patients with HCV-related chronic liver disease attending the Infectious Diseases Unit of the A.O.U. Federico II of Naples from January 2017 to March 2018 and treated with DAAs. For each patient, a fecal sample was collected and analyzed for the assessment of microbial diversity before the start of therapy and by SVR12 time. We excluded patients who had received antibiotics in the previous 6 months. Twelve patients were enrolled (6 male, 8 genotype 1 (1 subtype 1a), 4 genotype 2). Fibrosis scores were F0 in 1 patient, F2 in 1 patient, F3 in 4 patients and cirrhosis in the remaining 6 (all in Child-Pugh class A). All were treated with DAAs for 12 weeks (5 with Paritaprevir-Ombitasvir-Ritonavir-Dasabuvir, 3 with Sofosbuvir-Ledipasvir, 1 with Sofosbuvir-Ribavirin, 1 with Sofosbuvir-Daclatasvir, 1 with Sofosbuvir-Velpatasvir) and 100% achieved SVR12. In all patients, we observed a trend in reduction of potentially pathogenic microorganisms (i.e., Enterobacteriaceae). Furthermore, a trend of increase in α-diversity was observed in patients by SVR12 compared to baseline. This trend was markedly more evident in patients without liver cirrhosis than in those with cirrhosis. Our study shows that viral eradication obtained with DAA is associated with a trend in restoring the heterogeneity of α-diversity and in reducing the percentage of potentially pathogenic microbial species, although this benefit is less evident in patients with cirrhosis. Further studies with larger sample size are needed to confirm these data.
- Published
- 2023
23. Monoclonal Antibodies against SARS-CoV-2 Infection: Results from a Real-Life Study before the Omicron Surge.
- Author
-
Scotto R, Buonomo AR, Zumbo G, Di Fusco A, Esposito N, Di Filippo I, Nobile M, Pinchera B, Schiano Moriello N, Villari R, Gentile I, and Federico Ii Covid Team
- Abstract
Despite the lightning-fast advances in the management of SARS-CoV after 2 years of pandemic, COVID-19 continues to pose a challenge for fragile patients, who could benefit from early administration of monoclonal antibodies (mAbs) to reduce the risk of severe disease progression. We conducted a prospective study to evaluate the effectiveness of mAbs against SARS-CoV-2 among patients at risk for severe disease progression, namely elderly and those with comorbidities, before the omicron variant surge. Patients were treated with either casirivimab/imdevimab, sotrovimab, or bamlanivimab/etesevimab. The rates and risk factors for clinical worsening, hospitalization, ICU admission and death (unfavorable outcomes) were evaluated. A stratified analysis according to the presence of SARS-CoV-2 IgG was also performed. Among 185 included patients, we showed low rates of unfavorable outcomes (9.2%), which were more frequent in patients with chronic kidney disease (aOR: 10.44, 95% CI: 1.73−63.03; p < 0.05) and basal D-dimer serum concentrations > 600 ng/mL (aOR 21.74, 95% CI: 1.18−397.70; p < 0.05). Patients with negative SARS-CoV-2 serology at baseline showed higher C-reactive protein values compared with patients with positive serology (p < 0.05) and a trend toward a higher admission rate to SICU and ICU compared with patients with positive serology. Our results thus showed, in a real-life setting, the efficacy of mAbs against SARS-CoV-2 before an Omicron surge when the available mabs become not effective.
- Published
- 2022
- Full Text
- View/download PDF
24. COVID-19 Post-Exposure Evaluation (COPE) Study: Assessing the Role of Socio-Economic Factors in Household SARS-CoV-2 Transmission within Campania Region (Southern Italy).
- Author
-
Gentile I, Iorio M, Zappulo E, Scotto R, Maraolo AE, Buonomo AR, Pinchera B, Muto G, Iervolino C, Villari R, Schiano Moriello N, Scirocco MM, Triassi M, Paternoster M, Russo V, Viceconte G, and Federico Ii Covid-Team
- Subjects
- Economic Factors, Humans, Italy epidemiology, Retrospective Studies, COVID-19 epidemiology, SARS-CoV-2
- Abstract
Campania is the sixth poorest region of Italy, and it is the region with the highest income inequality. The secondary attack rates of SARS-CoV-2 among households are found to be substantially heterogeneous among published studies and are influenced by socio-economic factors. We conducted a retrospective study to describe the role of socio-economic factors in the household transmission of SARS-CoV-2 among patients living in Campania Region and referring to "Federico II" Hospital. We interviewed 413 subjects followed-up for COVID-19 between the 8 March 2020 and the 24 May 2021 with the aim to collect demographic, clinical, economic, and social data regarding their household and the index cases. The variables associated with SARS-CoV-2 attack rate higher than 50% among households were higher age ( p = 0.023) and higher Charlson Comorbidity Index of the index case ( p = 0.023) and, for household characteristics, higher number of families per house ( p = 0.02), location of the houses in Naples' suburbs (Chi
2 = 5.3, p = 0.02) and in Caserta City area (Chi2 = 4, p = 0.04), and renting the house compared to owning it (Chi2 = 5.83, p = 0.01). This study confirms the finding described by other authors that household transmission of SARS-CoV-2 is correlated with the income inequality of the analyzed geographical area as well as with the indicators of health and economic wealth of the families, and this correlation also applies to the Campania Region.- Published
- 2022
- Full Text
- View/download PDF
25. Risk of professional accidental exposure to biological agents in health care workers: a retrospective analysis carried out in a southern Italian tertiary hospital.
- Author
-
Bianco V, Spera AM, Maraolo AE, Parente S, Donno D, Schiano Moriello N, and Tosone G
- Subjects
- Adult, Allied Health Personnel statistics & numerical data, Female, Humans, Incidence, Italy, Male, Medical Laboratory Personnel statistics & numerical data, Medical Staff, Hospital statistics & numerical data, Midwifery statistics & numerical data, Nursing Staff statistics & numerical data, Post-Exposure Prophylaxis, Retrospective Studies, Risk, Students, Health Occupations statistics & numerical data, Tertiary Care Centers, Blood-Borne Pathogens, Health Personnel statistics & numerical data, Needlestick Injuries epidemiology, Occupational Exposure statistics & numerical data
- Abstract
Worldwide the needlestick injuries of health care workers (HCWs) still represent a major health problem. The authors aimed to evaluate the risk of HCW needlestick injuries in a tertiary university hospital in southern Italy in relation to some HCW characteristics (age, sex, professional profile, work department) and the source of infection. All HCWs of the University Hospital "Federico II" in Naples, Italy, attending the Infectious Diseases Unit after potential accidental contact to blood-borne viruses through needlestick injuries were enrolled during a 22-year period. HCWs underwent clinical analysis and were administered a specific questionnaire to collect (in anonymous fashion) data about age, sex, professional profile and work department. From 1995 to 2016 1,477 needlestick injuries in the same number of people (one accident per person) were recorded by our service. The HCWs were predominately males (n = 806, 55%) and the mean age was 39.4 years (±10.1 SD). The job categories most involved were: physicians (41%), followed by nurses (33%) and healthcare assistants (HCAs, 10%). The incidence proportion was calculated for these highest-risk categories in three defined time points (at the beginning, in the middle and at the end of the study period): 104/2149 (4.86%) in 1995, 41/2498 (1.64%) in 2005 and 25/2057 (1.22%) in 2015. Most injuries occurred in General Surgery (14.21%), Gynecology and Obstetrics (9%) and Pediatrics (6.49%). In about 34% the HCWs had been exposed to HCV infected fluids. Over time, a significant decrease in accidental exposure was recorded for physicians (p= 0.019), nurses (p< 0.0001) and HCAs (p< 0.0001). Our results confirm that some profiles, namely physicians, nurses and healthcare assistants, are still at risk of needlestick injuries, especially in surgical areas, including obstetric wards. Further primary and secondary prevention strategies are needed to decrease the incidence of new cases of needlestick injuries.
- Published
- 2019
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.